Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Observer-blinded, 3-part, Dose Escalation and Expanded Safety and Dose Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1

NCT05432583 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05432583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05432583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Observer-blinded, 3-part, Dose Escalation and Expanded Safety and Dose Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1
Lead sponsor
BioNTech SE
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 8, 2022
Completion date
October 31, 2026
Enrollment
318 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

genital herpes simplex type 2